A2 Review article in a scientific journal
Aivojen magneettikuvaus MS-taudin immunologisen hoidon seurannassa




List of Authors: Elovaara I, Soilu-Hänninen M, Kuusisto H, Martola J, Tienari P, Färkkilä M, Remes AM
Publication year: 2015
Journal: Duodecim
Volume number: 131
Issue number: 17

Abstract


Magnetic resonance imaging of the brain is currently the most sensitive method in detecting the lesions caused by multiple sclerosis. Assessment of the immunological treatment response used in the treatment of multiple sclerosis should be based on the clinical picture and brain MRI. T2-, flair- and T1-biased images, gadolinium enhancement and assessment of atrophy are required for MRI monitoring. In the first-line immune therapy MRI is taken at 6 to 12 months after starting the drug therapy, in fingolimod therapy after 6 to 12 months and 1 to 2 years, respectively, and in alemtuzumab and natalizumab therapy after one and two years



Last updated on 2019-21-08 at 20:28